Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Targeted cancer therapy stories

Nov 16, 2026

FDA approves Roche's oral breast cancer pill Wilserdly

The FDA approved Roche's oral treatment for estrogen receptor-positive, HER2-negative advanced breast cancer, providing a new option for patients and a significant commercial boost for the Swiss drugmaker.

Nov 16, 2026·3 sources
00
Nov 10, 2026

FDA approves Merck KGaA's pimicotinib for tenosynovial giant cell tumor

The FDA has approved pimicotinib (Pimjetmi, EMD Serono) for treating symptomatic tenosynovial giant cell tumors where surgery would worsen functional limitations, marking another win for Merck KGaA's rare tumor strategy.

Nov 10, 2026·3 sources
00
Nov 5, 2026

FDA grants J&J accelerated approval for head and neck cancer treatment

The FDA granted accelerated approval to Johnson & Johnson's treatment for patients with advanced head and neck cancer whose disease has worsened after prior therapy.

Nov 5, 2026·2 sources
00

Revolution Medicines' pancreatic cancer drug Rasonque posts record launch

Revolution Medicines' RAS inhibitor Rasonque is tracking as the best cancer drug launch in history by early sales metrics, with Wall Street analysts resetting projections upward. Company executives cautioned it is too early to draw firm conclusions.

Nov 5, 2026·3 sources
00

Alethio Therapeutics raises $90M Series A for rare blood cancer antibody

Oxford spinout Alethio Therapeutics secured $90 million in Series A funding to advance an antibody treatment for myeloproliferative neoplasms, a group of rare blood cancers.

Nov 5, 2026·2 sources
00
Oct 30, 2026

Fox Chase Cancer Center identifies ANO6 protein as target to slow pancreatic cancer growth

Researchers at Fox Chase Cancer Center discovered that blocking the anoctamin 6 (ANO6) protein can slow pancreatic tumor growth and reduce immune suppression in preclinical trials. The study reveals that cancer-associated fibroblasts transfer membrane lipids to cancer cells through ANO6-dependent trogocytosis, fueling tumor progression.

Oct 30, 2026·2 sources
00
Oct 29, 2026

METTL13 enzyme found to fuel cancer growth by boosting KRAS protein production

Researchers at MD Anderson Cancer Center discovered that the METTL13 enzyme modifies translation machinery to selectively enhance production of cancer-driving proteins like KRAS, offering a potential new therapeutic target upstream of existing KRAS-targeted drugs that face resistance issues.

Oct 29, 2026·3 sources
00
Oct 27, 2026

Asciminib shows stronger suppression of leukemia protein than existing treatments in new study

A study led by Adelaide University and SAHMRI provides the first direct evidence that asciminib, a targeted therapy for chronic myeloid leukemia, can rapidly and consistently suppress the cancer-driving protein within one week, offering a more effective and better-tolerated treatment option for CML patients.

Oct 27, 2026·2 sources
00

Mayo Clinic study finds cerebrospinal fluid liquid biopsy detects brain tumor DNA

A Mayo Clinic study published in the Journal of Neuro-Oncology demonstrates that analyzing DNA in cerebrospinal fluid can provide diagnostic information for brain tumors when MRI imaging is unclear or tissue biopsy is difficult or unsafe to obtain.

Oct 27, 2026·2 sources
00
Oct 26, 2026

FDA expands talazoparib approval for metastatic prostate cancer

The FDA approved the PARP inhibitor talazoparib in combination with enzalutamide for treatment of patients with metastatic androgen pathway modulation-naive or -sensitive prostate cancer.

Oct 26, 2026·2 sources
00

Genmab's ovarian cancer drug cuts death risk 57% in late-stage trial

Genmab's experimental antibody-drug conjugate Rina-S reduced the risk of death by 57% compared to chemotherapy in patients with advanced ovarian cancer, according to phase 3 trial results presented at ESMO. The Danish drugmaker's shares surged over 12% on the news.

Oct 26, 2026·2 sources
00
Oct 25, 2026

Roche's divarasib cuts death risk 44% in lung cancer trial vs Amgen, Bristol Myers drugs

Roche's next-generation KRAS G12C inhibitor divarasib reduced the risk of death by 44% compared to current treatments in previously treated mutant non-small cell lung cancer patients, with median overall survival reaching nearly 6 months longer than competitors.

Oct 25, 2026·4 sources
00

AstraZeneca's sone-ve extends overall survival in advanced stomach cancer trial

AstraZeneca's experimental antibody-drug conjugate sone-ve doubled survival time in patients with advanced stomach cancer who had received at least two prior treatments, exceeding analyst expectations in late-stage trial data.

Oct 25, 2026·2 sources
00
Oct 23, 2026

Real-world study confirms Lu-PSMA-617 benefits for metastatic prostate cancer patients

Results from France's early-access program demonstrate that PSMA-targeted radiopharmaceutical therapy Lu-PSMA-617 is safe and effective for patients with metastatic castration-resistant prostate cancer in routine clinical practice, confirming findings from controlled trials.

Oct 23, 2026·4 sources
00

Novartis breast cancer drug Kisqali cuts death risk by 19% after six years in early-stage trial

Novartis reported that its drug Kisqali helped extend survival for women with high-risk, early-stage breast cancer, cutting their risk of death by 19% after six years in trial data.

Oct 23, 2026·2 sources
00

Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Tango Therapeutics reported an 82% tumor response rate in a clinical trial combining targeted drugs for advanced pancreatic cancer, presented at ESMO congress.

Oct 23, 2026·2 sources
00

RCSI study identifies new treatment targets for most common type of colorectal cancer

An international research team led by RCSI University of Medicine and Health Sciences and The Institute of Cancer Research, London has identified potential new treatment approaches for microsatellite-stable colorectal cancer, the most common type in Ireland. The study provides a roadmap for repurposing existing drugs to treat this cancer subtype.

Oct 23, 2026·3 sources
00

New analysis shows daraxonrasib survival benefits across patient groups in advanced pancreatic cancer

A new analysis of a phase 3 clinical trial presented at ESMO 2026 found that daraxonrasib, a recently approved targeted therapy, improved survival compared with standard chemotherapy across multiple patient groups with advanced pancreatic cancer. The drug represents the biggest advance in decades against the notoriously hard-to-treat disease.

Oct 23, 2026·4 sources
00
Oct 22, 2026

Molecular glue RPT04402 stabilizes PP2A protein to inhibit lung and uterine cancer development

Researchers have developed RPT04402, a molecular glue that stabilizes protein phosphatase 2A (PP2A), a key regulator of cell signaling pathways frequently disrupted in tumors. The compound shows promise in inhibiting non-small cell lung cancer and uterine cancer development.

Oct 22, 2026·3 sources
00
Oct 7, 2026

FDA approves Pfizer's TUKYSA as first-line maintenance treatment for HER2+ metastatic breast cancer

The FDA approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a chemotherapy-free maintenance treatment for adults with HER2-positive metastatic breast cancer. The approval was supported by data showing more than 50% improvement in median progression-free survival.

Oct 7, 2026·4 sources
00
Aug 13, 2026

Taiho and Cullinan's zipalertinib succeeds in phase 3 lung cancer trial

Taiho Oncology and Cullinan Therapeutics announced their next-generation EGFR inhibitor zipalertinib significantly improved progression-free survival in a registrational phase 3 trial for first-line treatment of advanced non-small cell lung cancer. The results position the drug as a competitor to multiple approved medicines in the EGFR-mutated lung cancer market.

Aug 13, 2026·4 sources
00
Aug 7, 2026

New Research Reveals Ferroptosis Vulnerability in FLT3-Mutated Acute Myeloid Leukemia, Advancing Treatment Options

A Nature Cell Biology study identifies a novel therapeutic vulnerability in acute myeloid leukemia with FLT3 mutations, showing that FLT3 inhibitors trigger ferroptosis in cancer cells. The findings complement ongoing advances in FLT3-ITD+ AML treatment, including improved minimal residual disease testing and updated clinical practice guidelines.

Aug 7, 2026·3 sources
00
Jun 9, 2026

GSK Acquires Nuvalent for $10.6 Billion to Expand Cancer Drug Portfolio

UK pharmaceutical giant GSK has entered an agreement to acquire U.S.-based cancer drugmaker Nuvalent for $10.6 billion, adding targeted cancer therapies to its portfolio in one of the year's largest biopharma acquisitions.

Jun 9, 2026·3 sources
00

Top claims

  • ▪The FDA approved Roche Holding AG's oral breast cancer pill Wilserdly for patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer
  • ▪The approval of Wilserdly expands Roche Holding AG's footprint in an emerging class of medicines aimed at reshaping treatment for HR-positive breast cancer
  • ▪ESR1 gene mutations indicate that an estrogen receptor-positive breast tumor is developing resistance to standard therapies

People involved

Jia Guo

Subtopics

Cancer & Oncology21Cancer treatment12Clinical trials11Cancer research9Cancer treatment breakthroughs8Drug Policy, Pricing & Approval8Oncology7FDA drug approval6Drug development5Pharmaceutical Industry5Biomedical research4Cancer and Cancer Treatment3Cancer Treatment & Therapies3Precision medicine3Cancer2Drug Approval and Clinical Trials2Drug repurposing2Hematology & Blood Cancers2Molecular biology2Rare diseases2Accelerated approval pathways1Advanced drug delivery formulations1Biologic therapies1Biotech innovation1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories